In the brain-computer interface sector, Precision Neuroscience secured $102 million in Series C funding to advance its implant technology for people with paralysis. Meanwhile, Becton, Dickinson and Company settled with the SEC for $175 million over misleading investors about its Alaris infusion pump's flaws. Other industry updates include Terray Therapeutics' partnership with Gilead Sciences and Intrivo's pivot to an AI-powered weight loss coach. Additionally, Congress is close to extending pandemic-era telehealth exemptions for two more years.
Key takeaways:
- The Department of Health and Human Services (HHS) has released its AI Use Case Inventory, showing a significant increase in AI tools used internally, with a focus on text-based tasks and some tools already retired.
- A study in JAMA Pediatrics highlights concerns about AI and machine learning-enabled medical devices for children, noting many were validated on adult data, potentially leading to worse outcomes for pediatric patients.
- Precision Neuroscience has secured $102 million in Series C funding to advance brain-computer interface technology, despite broader industry challenges with capital constraints.
- The SEC settled with Becton, Dickinson and Company for $175 million over misleading investors about its Alaris infusion pump, which had known software flaws and regulatory issues.